Sunquest and N-of-One are aiming to help pathologists create actionable, patient-specific genetic reports from NGS panels.
N-of-One will help Agena interpret cancer genomic data generated by its MassArray system as part of a recently launched reporting network.
One deal will see Philips' solution used to improve cancer patient outcomes while the other will beef up its ability to interpret data from oncology tests.
N-of-One will interpret data from HemeSeq profiles for acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and other cancers.
N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.
N-of-One will use the funds to develop new oncology clinical decision support solutions, and to expand its sales and marketing efforts.
N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.
N-of-One will provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.
N-of-One will provide clinical and scientific evidence that supports personalized treatment recommendations made on the basis of WuXi Nextcode's tumor-normal sequence interpretation.
N-of-One has launched a new service called PrecisionInsights through which it will provide clinical interpretation for small, targeted gene panels.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.